Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
Gain-of-function mutations in the catalytic subunit of phosphoinositide-3-kinase (PI3KCA) occur frequently in breast cancer. Kalinsky and colleagues show that PI3KCA mutations are associated with favorable clinicopathologic features and better clinical outcome, including survival. These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway.
Di Cosimo
Serena
S
Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
Baselga
José
J
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D058534:Class I Phosphatidylinositol 3-Kinases; D016503:Drug Delivery Systems / Q000379:methods; D004789:Enzyme Activation / Q000235:genetics; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008954:Models, Biological; D009154:Mutation / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors
D000970:Antineoplastic Agents; D058534:Class I Phosphatidylinositol 3-Kinases; D004791:Enzyme Inhibitors; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; C484760:PIK3CA protein, human